Curated News
By: NewsRamp Editorial Staff
June 18, 2025
Nutriband and Kindeva Scale Up Abuse-Deterrent Opioid Patch Production
TLDR
- Nutriband's Aversa Fentanyl patch, developed with Kindeva, offers a competitive edge as the first abuse-deterrent opioid patch, targeting peak U.S. sales of $80-$200 million.
- Nutriband and Kindeva scaled up Aversa Fentanyl's manufacturing, combining AVERSA technology with an FDA-approved fentanyl patch, next steps include clinical supplies and an IND application.
- Aversa Fentanyl's abuse-deterrent technology aims to reduce opioid misuse, contributing to a safer healthcare environment and better patient outcomes globally.
- Discover how Nutriband's innovative AVERSA technology is set to revolutionize opioid treatment with the world's first abuse-deterrent fentanyl patch.
Impact - Why it Matters
This news is crucial as it highlights a significant step forward in addressing the opioid crisis through innovative technology. The development of an abuse-deterrent opioid patch like Aversa Fentanyl could drastically reduce the potential for misuse and abuse of powerful painkillers, offering a safer alternative for patients in need. The collaboration between Nutriband and Kindeva exemplifies how partnerships can lead to breakthroughs in pharmaceutical safety and efficacy, potentially saving lives and reducing the societal impact of opioid abuse.
Summary
Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva, a global CDMO, has successfully scaled up the commercial manufacturing process of Aversa Fentanyl, a pioneering abuse-deterrent opioid patch. This product combines Nutriband's AVERSA technology with Kindeva's FDA-approved fentanyl patch, aiming to address the critical issue of opioid abuse. The next steps include producing clinical supplies and submitting an Investigational New Drug application for a human abuse liability study. With projections of peak U.S. sales between $80 million and $200 million, Aversa Fentanyl represents a significant advancement in the fight against opioid misuse, supported by Nutriband's extensive international patent portfolio. For more details, visit https://ibn.fm/EJwVT.
Nutriband is at the forefront of developing transdermal pharmaceutical products designed to prevent drug abuse. Their AVERSA technology is a game-changer, offering a solution to the abuse, misuse, and accidental exposure of potent drugs. Learn more about their innovative approach at www.Nutriband.com. This development is a testament to the potential of collaborative innovation in creating safer pharmaceutical options.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband and Kindeva Scale Up Abuse-Deterrent Opioid Patch Production
